Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy
Reads0
Chats0
TLDR
The potential for use of psilocybin and psilocin as a treatment agent in neuropsychiatry has been investigated in this article , where the potential for harm is also assessed.Abstract:
Abstract Psilocybin is a tryptamine alkaloid found in some mushrooms, especially those of the genus Psilocybe. Psilocybin has four metabolites including the pharmacologically active primary metabolite psilocin, which readily enters the systemic circulation. The psychoactive effects of psilocin are believed to arise due to the partial agonist effects at the 5HT2A receptor. Psilocin also binds to various other receptor subtypes although the actions of psilocin at other receptors are not fully explored. Psilocybin administered at doses sufficient to cause hallucinogenic experiences has been trialed for addictive disorders, anxiety and depression. This review investigates studies of psilocybin and psilocin and assesses the potential for use of psilocybin and a treatment agent in neuropsychiatry. The potential for harm is also assessed, which may limit the use of psilocybin as a pharmacotherapy. Careful evaluation of the number needed to harm vs the number needed to treat will ultimately justify the potential clinical use of psilocybin. This field needs a responsible pathway forward. read more
Citations
More filters
Journal ArticleDOI
Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptoms
Patrick D. Skosnik,Jordan Sloshower,Hamideh Safi-Aghdam,Surbhi Pathania,Shariful A. Syed,Brian Pittman,Deepak Cyril D'Souza +6 more
TL;DR: In this article, a double-blind, placebo-controlled, within-subject study, individuals with major depressive disorder (MDD; n = 19) were administered placebo followed by psilocybin (0.3 mg/kg) in a fixed order (placebo, then psilokine 4 weeks later).
Journal ArticleDOI
Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive–compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial
Terence H. W. Ching,Rachael G. Grazioplene,Stephen A. Kichuk,Giuliana DePalmer,Ella D'Amico,Jeffrey Eilbott,Michelle C. Burke,Bradford S. Martins,Prerana Patel,Christopher Pittenger,Ben Kelmendi +10 more
TL;DR: In this paper , the authors evaluated the feasibility, safety, and tolerability of psilocybin in the treatment of OCD, and elucidated neural mechanisms that may mediate the effects of the drug on OCD.
References
More filters
Journal ArticleDOI
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.
Roland R. Griffiths,Matthew W. Johnson,Michael A. Carducci,Annie Umbricht,William A. Richards,Brian D Richards,Mary P Cosimano,Margaret A. Klinedinst +7 more
TL;DR: High-dose psilocybin produced large decreases in clinician- and self-rated measures of depressed mood and anxiety, along with increases in quality of life, life meaning, and optimism, and decreases in death anxiety.
Journal ArticleDOI
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial
Stephen Ross,Anthony P. Bossis,Jeffrey Guss,Gabrielle Agin-Liebes,Tara C. Malone,Barry H. Cohen,Sarah E. Mennenga,Alexander B. Belser,Krystallia Kalliontzi,James Babb,Zhe Su,Patricia Corby,Brian L. Schmidt +12 more
TL;DR: Psilocybin was associated with enduring anxiolytic and anti-depressant effects in patients with cancer-related psychological distress, sustained benefits in existential distress and quality of life, as well as improved attitudes towards death.
Journal ArticleDOI
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Charles S. Grob,Alicia L. Danforth,Gurpreet S. Chopra,Marycie Hagerty,Charles R. McKay,Adam L. Halberstadt,George R. Greer +6 more
TL;DR: This study established the feasibility and safety of administering moderate doses of psilocybin to patients with advanced-stage cancer and anxiety and revealed a positive trend toward improved mood and anxiety.
Journal ArticleDOI
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Robin L. Carhart-Harris,David Erritzoe,Timothy Williams,James M. Stone,Laurence J. Reed,Alessandro Colasanti,Robin J. Tyacke,Robert Leech,Andrea Malizia,Kevin Murphy,Peter Hobden,John Evans,Amanda Feilding,Richard G. Wise,David J. Nutt +14 more
TL;DR: Psilocybin caused a significant decrease in the positive coupling between the mPFC and PCC, which strongly imply that the subjective effects of psychedelic drugs are caused by decreased activity and connectivity in the brain's key connector hubs, enabling a state of unconstrained cognition.
Journal ArticleDOI
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action.
Franz X. Vollenweider,Margreet F. I. Vollenweider-Scherpenhuyzen,Andreas Bäbler,Helen Vogel,Daniel Hell +4 more
TL;DR: In healthy human volunteers, the psychotomimetic effects of psilocybin were blocked dose-dependently by the serotonin-2A antagonist ketanserin or the atypical antipsychotics risperidone, but were increased by the dopamine antagonist and typical antipsychotic haloperidol.
Related Papers (5)
Therapeutic usefulness of hallucinogenic drugs as a function of their chemical structure.
R Fischer,H Goldman +1 more